Free Trial

Quest PharmaTech Q1 2024 Earnings Report

Quest PharmaTech logo
C$0.02 -0.01 (-33.33%)
As of 02/21/2025 12:52 PM Eastern

Quest PharmaTech EPS Results

Actual EPS
-C$0.03
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Quest PharmaTech Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Quest PharmaTech Announcement Details

Quarter
Q1 2024
Time
N/A

Conference Call Resources

Quest PharmaTech Earnings Headlines

Quest PharmaTech Inc (QPT)
Watch This Robotics Demo Before March 17th
Jeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... Just did a demo of what Nvidia’s CEO said will be "the first multitrillion-dollar robotics industry."
Quest PharmaTech Announces Results from AGM
See More Quest PharmaTech Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Quest PharmaTech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Quest PharmaTech and other key companies, straight to your email.

About Quest PharmaTech

Quest PharmaTech (CVE:QPT), a pharmaceutical company, engages in the development of novel therapeutics for the treatment of targeted cancer. Its lead product candidate is Mab AR 9.6 against truncated O-glycan on MUC16, for targeted cancer therapy applications. The company also offers Oregovomab, which is in Phase III clinical trial for the treatment of ovarian cancer. In addition, it develops, manufactures, and commercializes immunotherapy products for pancreatic cancer; and combinatorial immunotherapeutic products for the treatment cancer by using monoclonal antibodies of the immunoglobulin of G and E class. Quest PharmaTech Inc. is headquartered in Edmonton, Canada.

View Quest PharmaTech Profile

More Earnings Resources from MarketBeat